Effects of atomoxetine on self-reported high-risk behaviors and health-related quality of life in adolescents with ADHD.

AbstractObjective:This study measured the effects of atomoxetine HCl on high-risk behaviors and health-related quality of life in adolescents with attention-deficit/hyperactivity disorder (ADHD), using a subgroup analysis of data from a previous clinical trial.Research design and methods:In the base study, which was conducted at 26 sites in the United States, patients ages 13–16 years were randomized in a double-blind manner to atomoxetine treatment by one of two dose titration schedules for 8 weeks. Patients who responded to treatment were rerandomized to atomoxetine at a daily dose of 0.8 or 1.4 mg/kg for 40 weeks. Patients in the highest-risk quartile for each category of behavior or domain were included and the dosing groups combined.Main outcome measures:Efficacy measures included the Youth Risk Behavior Surveillance (YRBS) and Child Health and Illness Profile – Adolescent Edition (CHIP-AE). The YRBS has six categories of behavior, and the CHIP-AE has six domains. Data for mean change from baseline w...